This trial compared skin blood flow, temperature and incidence of venous leg ulcers in patients with chronic venous disease using compression wraps and elevation pillows. Patients with CEAP C4 skin damage and C5 history of ulcers were randomly assigned to a cryotherapy intervention (n = 138) or placebo cuff control (n = 138) applied to the lower legs over 9 months. The time the ulcers healed prior to enrollment in the study for the cryotherapy group ranged from 1 to 2218 days (n = 8, median = 32 days); for the control group, the range was 24 to 489 days (n = 6, median = 390 days). There were no statistically significant blood flow changes measured in perfusion units with a laser Doppler flowmetre within or between the groups; mean difference between the groups was 0⋅62, P = 0⋅619. No differences were noted in skin temperature measured with an infrared thermometer within and between the groups; mean difference between the groups was −0⋅17 ∘ C, P = 0⋅540. Cryotherapy did not improve skin blood flow or temperature and did not show efficacy in preventing ulcers. However, at least 30% of intervention and 50% of control participants were anticipated to develop an ulcer during the study; only ∼7% occurred. These findings suggest that strict adherence to standard of care decreases the incidence of leg ulcers and remains a best practice for leg ulcer prevention.
Introduction
Few medical therapies prevent venous leg ulcers (VLUs) associated with chronic venous insufficiency (CVI). Compression is the mainstay of prevention; however, for the more severe stages of CVI, where leg skin damage or VLUs are prevalent, and compression has not performed ideally, approximately 70-90% of VLUs recur (1) . Chronic skin inflammation is one of the major pathological processes and is associated with elevated skin temperature and increased microcirculatory blood flow that contributes to skin damage and VLU recurrence (2) .
Cryotherapy is a promising adjuvant therapy to reduce skin temperature and microcirculatory blood flow in inflamed, CVI-affected skin. Our early trials suggest that cryotherapy or cooling the lower leg is associated with decreased skin temperature and blood flow in inflamed CVI skin (3); however, little is known about whether long-term cryotherapy prevents VLUs in high-risk patients. We conducted a randomised [ Correction added on 19 August 2016, after first online publication: a typographical error in "cryotherapy" has been corrected.] double-blinded placebo-controlled trial to determine whether a 9-month cryotherapy intervention was associated with a reduced incidence of VLUs in people with advanced CVI Clinical, Etiological, Anatomical, Pathophysiological (CEAP) stages C4 (skin damage) and C5 (history of leg ulcers). The study treatment involved a dosed application of a cryotherapy cuff to the affected skin while elevating the leg on a special pillow. We hypothesised that a dosed cryotherapy regimen that
Key Messages
• this randomised trial of 276 patients with chronic venous insufficiency compared skin blood flow, skin temperature and venous leg ulcer incidence between a cryotherapy intervention group and a 'sham' control group; both groups received standard of care, including compression and leg elevation • there were no statistically significant differences within and between groups in skin blood flow and skin temperature
• the overall incidence of ulcers was approximately 7%, much lower than the anticipated 30% and 50% for the cryotherapy and control groups, respectively • cryotherapy added no additional benefit over the sham control group when strict standard of care is provided as part of the intervention started with intense daily cryotherapy of the lower-leg skin with a cryotherapy cuff, as compared with a non-cryotherapy 'sham' cuff, would decrease the skin temperature, microcirculatory blood flow and incidence of VLUs. Based on epidemiological studies of the incidence of VLUs, we expected a 30% recurrence rate in the cryotherapy group and 50% in the control group (4). For participants who developed VLUs, we sought to determine whether there were differences in demographics and clinical characteristics that would provide a 'prediction' model. The overall long-term objective was to contribute to an enhanced practice standard for VLU prevention.
Materials and methods
The study was a parallel-design randomised double-blinded placebo-controlled clinical trial. Participants were randomised to one of two groups: a cryotherapy-cuff intervention or the sham cuff-control condition. Both groups received standard of care, which included a compression cuff worn during waking hours but removed during treatments and leg elevation on a wedge pillow. The study was performed in six locations, including wound centres, one nurse practitioner's practice and one research outpatient clinic located in South Carolina and Georgia between September 2010 and December 2015. In addition to study visits, patients received supportive phone calls daily or on the first three days of the study to clarify and reinforce study procedures and to answer questions, then weekly during month 1, bi-weekly during months 2 and 3 and then monthly through the end of the study to encourage adherence to the protocol and provide reminders of the upcoming study visits. Retention strategies included a cash prize drawing at each study visit and mailed study visit reminder cards. The institutional review board of the Medical University of South Carolina and Spartanburg Regional Medical Center approved the protocol. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Participants provided written informed consent and received $400 in study compensation.
Participant identification
Participants were recruited from the wound centres, nurse practitioner's practice and through referrals from vascular surgeons and primary/family care practices. In practice settings, providers approached potentially eligible patients who fit the inclusion criteria (e.g. recently healed VLU). Billboards, television advertisements, flyers and presentations at health fairs and other social events, such as support groups, were used to promote the study to individuals 21 years of age and older from the general public.
Inclusion and exclusion criteria
Study inclusion criteria included the diagnosis of a CVI C5 history of VLUs in the past 2 years or C4 inflammatory skin changes, such as eczema, hyperpigmentation, lipodermatosclerosis; ankle brachial index of 0⋅8-1⋅3 mmHg; intact sensory and thermal skin sensations; agreement to wear compression wraps during waking hours; accessibility by phone, email or mail; willingness to attend five study visits; ability to understand protocol by passing a verbal test after watching a DVD with standardised instructions; ability to perform protocol by adequately demonstrating required activities, such as taking leg temperature with thermal thermometer; and a working freezer. Exclusion criteria included having had surgical procedures on the leg in the past 12 months; open leg or foot ulcer; leg infection within the past month; inflammatory and vascular comorbid conditions such as lupus erythematosus, Raynaud's disease, scleroderma and lymphoedema; receiving chemotherapy; and current participation in another clinical trial.
Patient characteristics

Medical history
Medical history, including comorbid conditions, venous symptoms (i.e. itching, burning, pain) and medications, gender, race/ethnicity and medications taken, was obtained using patient report or chart data. Height and weight were obtained at baseline to calculate body mass index (BMI), m 2 /kg. Ankle and calf circumferences were collected in centimetres.
Primary outcomes
The outcomes of lower-leg skin blood flow (flux) and temperature and the incidence of VLUs were measured at the baseline visit (V1); during the active study period at the end of months 1 (V2), 3 (V3) and 6 (V4); and at the end of the three-month follow-up period at month 9 (V5) by assessors unaware of participants' group assignment.
Measures
Tissue perfusion (skin blood flow or flux), defined as the movement of red blood cells and reported in perfusion units (PU), was measured with a laser Doppler flowmetre (LDF) at a depth of 0⋅5-1 mm (Perimed, Stockholm, Sweden) at each visit using a standardised protocol. Participants were placed in a recumbent position, and the sensor from the LDF was affixed to skin 5 cm above the medial malleolus of the most severely affected leg. Legs were covered with a sheet to acclimatise for 15 minutes, after which skin blood flux was recorded. Skin temperature was then measured over this same site with an infrared thermometer (TempTouch, SanAntonio, TX) reported in Celsius. The incidence of VLUs was obtained by asking participants at each visit whether a VLU developed since the last visit. Participants were also instructed to immediately notify the researchers of a VLU, and VLUs were solicited during supportive phone calls. All data were recorded in the web-based Research Electronic Data Capture management system (REDCap).
Randomisation and study interventions
Stratified permuted block randomisation was used to assign eligible participants, stratified by site, that is, practice, wound centre and self-referral, to ensure equal participant allocation to the two treatment arms.
Cryotherapy intervention group
Participants received an inelastic ready-to-wear lower-leg compression system (JuxtaLite ® , CircAid ® by mediUSA, San Diego, CA) that included an undersleeve, compression anklet and legging. Using the built-in pressure system, 30 mmHg of compression was delivered at the ankle up through the calf. Participants were instructed to wear the system during waking hours and remove it during the application of the cryotherapy cuff (Southwest Technologies, Kansas City, MO). The cuff was applied to the most severely affected leg noted during the baseline visit. During cryotherapy, legs were elevated on a special pillow, which was also provided to the participants. The cryotherapy regimen was as follows: month 1, daily for 30 minutes; months 2-3, twice weekly for 30 minutes; months 4-6, once weekly for 30 minutes and months 7-9 (follow-up), PRN based on skin temperature. If temperatures increased 2⋅2 ∘ C over baseline (established as the mean of daily temperatures after 30 days of measures) for two consecutive days during the follow-up period, skin was cooled for 30 minutes daily, for five consecutive days. Participants measured skin temperature using the handheld infrared thermometer (TempTouch, San Antonio, TX) before the cryotherapy treatment, immediately after the treatment and 12 hours later, generally the next morning. They were instructed to conduct the treatment and temperature measurements at the same time each day. Cuffs were kept in the freezer set at −17⋅8 ∘ C. Freezer thermometers were provided, and participants were asked to record the freezer temperature, the times skin temperature readings were taken and the time of the treatment in study logs.
Control group
The procedure was identical to that of the intervention group. A 'sham' cuff was filled with cotton batting, also manufactured by Southwest, Kansas City, MO, and used as the placebo.
Statistics
Power calculations assumed that 192 people (96 in each group) completing the study would provide 85% power to detect a difference in proportions, with an odds ratio for the occurrence of a VLU of 0⋅39, assuming approximately 50% of participants experienced a VLU in the control group compared with 30% in the intervention group, = 0⋅05, two-sided test. We over-enrolled participants by 20% to account for an anticipated attrition rate based on our prior work (3). All analyses were conducted using SAS 9⋅4 (Cary, NC).
For the comparisons between groups for continuous and categorical variables, pooled t-tests and chi-square tests were used, respectively. Change in temperature and blood flux from baseline to the end of the active cryotherapy period (month 6) was compared within and between the intervention and control groups for those participants with measurements at both time points. Temperatures outside the possible range of 15⋅6-37⋅8 ∘ C and blood flux outside of four PU standard deviations (SD) were removed from analysis.
All longitudinal models were analysed using a mixed effects models approach, with clustering by participants to control correlation among repeated measurements. Dependent variables were study leg temperature and blood flux over the entire study period of 9 months. Fixed effects included group (intervention versus control) and site as a stratification variable. Potential covariates included demographics such as age, gender, race, marital status, employment and residence; clinical characteristics such as BMI and time since last VLU; and the time-varying covariates such as wearing compression stockings, ankle circumference and calf circumference, as well as potential effect modifiers. Potential covariates with a P-value < 0⋅2 in bivariate models were included in the full model. Model selection was carried out stepwise, manually removing the covariate with the highest P-value until only the covariates with 0⋅05 level of significance remained.
Results
Of the 347 participants with a scheduled baseline visit, 276 met eligibility criteria and were allocated into two groups ( Figure 1) ; 138 each in the intervention and control groups, respectively. The mean age was 61⋅8 years; BMI was 36⋅3 m 2 /kg, and ankle circumference 24⋅7 cm ( Table 1 ). The majority of participants were female (54⋅4%) and Black or African American (55⋅8%). More than half the sample (57⋅8%) had a history of VLU.
Change from baseline to 6 months
Blood flux
No statistically significant difference in blood flux was observed between groups ( Figure 2) . No statistically significant differences for change in skin blood flux from baseline to month 6 was observed, with a mean change of 10⋅8 to 9⋅5 PU for the intervention group (n = 93) and 10⋅5 to 9⋅8 PU in the control group (n = 90). The mean difference in the change in blood flux between the groups at month 6 was 0⋅62 PU (95% CI: −1⋅8-3⋅1; P = 0⋅619).
Skin temperature
When skin temperature was analysed from baseline to month 6, there was no statistically significant difference in the temperature between groups (Figure 2 ). Skin temperature changed from 30⋅7 ∘ C to 30⋅9 ∘ C in the intervention group (n = 98) and from 30⋅7 ∘ C to 31⋅1 ∘ C in the control group (n = 96). The mean difference in change in temperature between the groups was −0⋅17 ∘ C (95% CI: −0⋅73-0⋅38; P = 0⋅540).
347
Longitudinal analysis over 9 months
Incidence of VLUs
During the study, 18 patients developed VLUs on the study leg, 11 (9⋅6%) in the cryotherapy group and seven (5⋅9%) in the control group (P = 0⋅29). Of the 11 patients in the cryotherapy group that developed ulcers, eight patients (72⋅7%) had a previous VLU, while in the control group, six of the seven patients (85⋅7%) had a previous VLU within the past 2 years. For these participants, the time the ulcers healed prior to enrollment in the study for the cryotherapy group ranged from 1 to 2218 days (n = 8, median = 32 days); for the control group, the range was 24-489 days (n = 6, median = 390 days). Although numbers across both groups were too small to draw statistically valid inferences, a higher proportion of White males in the cryotherapy group (n = 6, 54⋅55%) compared with White males in the control group (n = 1, 14⋅29%) developed VLU. Black males in the control group (n = 3, 42⋅86%) compared with Black males in the cryotherapy group (n = 2, 18⋅18%) developed VLUs, although differences were not statistically significant. There were no apparent differences between Black and White females. Both Black and White males who developed VLUs were younger than their counterparts without VLUs. For example, Black males in the control group were, on average, 51⋅7 years, SD 8⋅1 years, compared with a mean age of 61⋅7 years, SD 9⋅3 years, in Black males without VLUs. White males in the cryotherapy group who developed VLUs were, on average, 59⋅0 years of age, SD 17⋅5 years, compared with a mean age of 65⋅4 years, SD 10⋅7 years, among White males who did not develop VLUs. Figure 3 shows the incidence of VLUs and causes between groups.
Blood flux and temperature
Ankle circumference was the only statistically significant variable associated with blood flux, indicating that for a 10-cm increase in ankle circumference, blood flux increased by 1⋅8 PU (P = 0⋅0032), controlling for treatment and site. Examination of skin temperatures showed that females' legs were almost a 1/2 ∘ C cooler than males' ( = −0⋅46, P = 0⋅0009), controlling for treatment, site and calf circumference. Conversely, calf circumference was statistically significantly associated with temperature, with a 0⋅26 ∘ C increase for every 10-cm increase in calf circumference (P = 0⋅0083), controlling for treatment, site and gender. There were no statistically significant differences in blood flux or temperature over the 9-month period between groups.
Predictive modelling for the development of VLUs could not be conducted because of the small number of subjects developing a VLU. A total of 14 participants out of the 18 who developed a VLU indicated that trauma was the causative factor associated with the development of the VLU. There were no adverse events reported from cryotherapy.
Discussion
In this randomised controlled trial (RCT), of 276 participants with C4 and C5 CVI, a home-based cryotherapy intervention applied to the lower legs to reduce inflammation did not significantly decrease skin blood flux or temperature. There was no difference between the intervention and control groups in the incidence of VLUs. This group of patients was targeted because they have the highest risk of developing VLUs, especially those with stage 5 CVI. These individuals tend to be older, obese and female; older age and higher BMI are risk factors for developing the disease, with an increased incidence of developing VLUs (5,6). Our findings are in contrast; more men developed VLUs than women and were younger. Both men and women with VLUs were obese. The younger men were more active, as noted by the types of skin injuries that led to VLUs, such as lacerations sustained during yard work, a work boot 'rubbing' a blister and hitting the lower leg on household objects such as tables. These skin injuries were considered VLUs because they required treatment from their wound care providers. It is well established that direct triggers, such as penetrating injuries, burns, blunt trauma and insect bites, account for approximately 75% of VLU recurrence (7). In our study, 77% were trauma-induced. We recognise that having a duplex investigation to demonstrate venous pathology would have provided more meaningful data upon which to base the diagnosis, a limitation of this study.
Based on our previous work, we hypothesised that skin blood flux and temperature would decrease in response to active cryotherapy, but we did not observe differences within or between groups. However, findings are dissimilar to those from our previous work. We found in our preliminary study of blood flux and temperature measured with a LDF and infrared thermometer, conducted across three weekly time periods in a controlled laboratory setting, that patients with CVI (n = 31) compared with those without CVI (n = 24) showed statistically significant higher blood flux at two time points (17⋅6 and 13⋅6 PU, P = 0⋅002 and 0⋅012, respectively) (8) . In this same study, skin temperature was higher at each time point by an average of 1⋅2 ∘ C (P = 0⋅008). We also found that CVI-affected skin at the ankle region is 1⋅8-2⋅2 ∘ C higher (8-10) compared with healthy skin that ranges from 29⋅6 ∘ C to 30⋅1 ∘ C (11, 12) . However, the current study findings of blood flux 7 PU lower and temperature 0⋅12 ∘ C lower at baseline suggest possible differences in the sample. Our sample was younger, which might suggest age differences associated with flux and temperature.
The lower values may be indicative of the location where skin measurement was standardised above the malleolus and not reflective of the area of inflammation or skin over the previously healed ulcer. In the earlier studies, the skin was tested over previously ulcerated or highly inflamed skin. The influence of wearing compression on a regular basis most likely positively influenced flux and skin temperature. In our previous study, we were unable to control the wearing of compression as we did not provide garments.
Microcirculatory dysfunction is well established in CVI because of microangiopathic changes and is closely correlated with inflammatory skin disorders consistent with those found in stage 4 CVI (e.g. venous eczema) (2, 13, 14) . These disturbances remain unchanged even after VLU healing, and when compared with healthy individuals, blood flux is often six to seven times higher (15) than the normal 3⋅9 PU (16) . Elevation in skin blood flux and temperature are partially explained by increased concentration and velocity of moving blood cells (17, 18) . Inflammation is also a major factor, which results from extravasated fluid and macromolecules that increase the metabolic activity, leading to tissue damage (19) . Thus, with the notion that 'skin heats up before it breaks down', we sought to cool it as a prevention intervention.
Cryotherapy, which reduces the metabolic activity of the skin, is noted for its therapeutic effects on inflammation. Studies of cryotherapy applied to chronically inflamed skin are limited (20) . In our preliminary 4-week study of 57 participants randomised to usual care (compression, elevation) or usual care plus application of a cryotherapy wrap for 30 minutes to CVI-affected skin, blood flux was significantly reduced by an average of 6 PU, from 15 to 9, P = 0⋅03. Skin temperature was reduced by 1 ∘ C; however, this reduction was not statistically significant, P = 0⋅77 (3). These preliminary signals of cryotherapy efficacy provided the basis upon which this RCT was designed as a longitudinal intervention study. Although the specific physiological mechanisms associated with cryotherapy for chronically inflamed skin are poorly understood, cryotherapy causes an initial vasoconstriction in skin blood vessels, which results in decreased local blood flux to the area (21) . Cryotherapy also prevents localised fluid leakage from the microcirculation and thus could reduce inflammation (i.e. oedema, redness, eczema). We extended our cryotherapy 'proof of concept' work to a prophylactic approach to decrease the risk of ulceration by reducing microcirculatory blood flux, vessel permeability and tissue metabolism. However, cryotherapy did not provide an added benefit to compression and leg elevation.
While there were no differences in the incidence of VLU between groups, the overall average incidence was extremely low (7%); epidemiological data suggest a 70% ulcer recurrence rate in CEAP C5 venous insufficiency (history of ulcers) and 50% occurrence rate in CEAP C4 (skin damage) from 3-18 months post-healing (22) . We collected data on the length of time the ulcer had been healed and found a wide range, especially in the treatment group, with one person enrolled after one day post-healing and another almost 6 years after. Conservatively, we estimated that at least 30% of patients in the intervention groups and 50% of controls would develop a VLU based on reports from the literature and consultation with our vascular team. We view our lower incidence rate in the experimental group as clinically important. It is equally important to note that this lower rate could be attributed to the use of compression, the mainstay of therapy for ulcer prevention. Future studies should document the length of time the ulcer has been healed and whether compression therapy was worn and the type.
Limitations
A major limitation of our study was that the skin site measured by the LDF and the infrared thermometer was standardised above the medial malleolus and did not necessarily reflect the actual blood flux or temperature of CVI-affected skin. Reductions over the affected area may not have been adequately captured, giving rise to a false negative outcome. Cutaneous blood flux is highly variable with a heterogeneous pattern, and regional differences have been reported around the ankle and dorsum of the foot (23) . Thus, measuring one small area may not be valid for measuring the effects of treatments, such as cryotherapy, that are applied regionally to the lower leg. Although the LDF measures total local microcirculatory blood flux, including the perfusion in the capillaries (nutritive flux), arterioles, venules and shunting vessels (thermoregulatory), the type, depth and distribution of these vessels in compromised skin are unknown. LDF provides a measure of acute effects of local blood flow changes; however, flux is poorly reproducible over time because of its extraordinary spatial and temporal variability. Unfortunately, we could not control for the depth of sample volume, particularly in lipodermatosclerotic skin, where the laser beam was not able to penetrate the thickened tissue to adequately detect movement of the cells. Both groups received the highest possible standard of care. Compression therapy and leg elevation are the hallmarks of VLU prevention. The compression wraps and wedge pillow used in this study were of high quality, and the self-monitoring approach was reinforced with regular phone calls and contact with study staff. Typically, adherence to compression alone is low. In a study of 16 770 patients with CVI, 25⋅6% used compression stockings, and almost half (46⋅6%) were never prescribed therapy (24) . 'Real world' usual care would require patients to obtain and pay for their own compression garments; they would not receive a pillow and would not be given a thermometer to monitor skin temperature; rather, they would be told to conduct these self-care activities themselves. Finally, our previously reported adherence to self-recording skin temperatures is fair (25) . We found numerous errors in recording temperatures at the right times; thus, it was unclear whether what was actually documented was the real temperature taken at the same time each day. Temperature could have been considerably higher than what they should have been, for example, 12 hours after cryotherapy.
Conclusions
A trial is underway to establish whether a cryotherapy patch compared with a placebo control patch will prevent VLUs and diabetic foot ulcer recurrence in patients with a history of these ulcers. Participants are instructed to wear compression, elevate the legs or wear appropriate foot wear, but compression wraps, pillows and footwear will not be provided. However, at this time, adding cryotherapy to clinical practice guidelines is not advised until results from definitive studies are available.
